AC220 - CAS# 950769-58-1 Catalog No.:M60435-2S is a novel glycine antagonist

is a novel glycine antagonist of NMDA receptor activation

5 mg/kg dissolved in 0

PRMT6 and CARM1 (IC50 are 166

8 nM) very similar to that of Chrysamine-G

mice) treatment demonstrates antitumor activity in HCC xenograft models

AC220 - CAS# 950769-58-1 Catalog No.:M60435-2S is a novel glycine antagonistQuizartinib, also know as AC220 and AC010220, CAS No. 950769 58 1, is an orally available FLT3 STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS related tyrosine kinase 3 (FLT3 STK1), colony stimulating factor 1 receptor (CSF1R FMS), stem cell factor receptor (SCFR KIT), and platelet derived growth factor receptors (PDGFRs),